G42 Launches OpenAI GPT-OSS Globally on Core42's AI Cloud
13.8.2025 18:26:00 CEST | Business Wire | Press release
Unmatched Performance. Silicon Freedom. Seamless access via Compass APIPowered by Compass API – run OpenAI’s open-weight models on your choice of leading GPUs and accelerators via an instant API. Optimized performance – Unmatched AI performance, with exceptional speed of up to 3,000 tokens per second per user, scalable for diverse AI workloads. For public sector, commercial, and developer workloads – delivers agentic, high-performance systems with scalable, sovereign controlled deployments.
Core42, a G42 company specializing in sovereign cloud and AI infrastructure, announced the availability of OpenAI’s latest open-weight AI models, including gpt-oss-20B and gpt-oss-120B, on the Core42 AI Cloud platform, instantly accessible through the Core42 Compass API. The deployment enables enterprises, researchers, and developers to run the models on a choice of leading silicon platforms with sovereign, scalable, and high-performance capabilities.
Integrated into Compass API with the flexibility to access a wide spectrum of high-performance compute platforms, Core42 delivers industry-leading inference speeds of up to 3,000 tokens per second per user, enabling real-time AI at global scale while aligning workloads with the optimal infrastructure for price-performance and scalability. This deployment delivers tailored performance for low-latency inference workloads and applications, reinforcing Core42’s commitment to secure and optimized global sovereign-enabled AI infrastructure.
“Core42 AI Cloud, powered by silicon-diverse infrastructure, delivers the flexibility and performance needed for today’s AI workloads,” said Kiril Evtimov, CEO of Core42and Group CTO, G42. “Through the Compass API, organizations can access the latest open-weight AI models and choose the optimal platform to scale transformation, optimize performance and cost, and drive progress across global markets.”
Key Benefits of Core42’s Open-Weight Deployment:
- Enterprise-scale performance – Run the fastest, most demanding workloads at global scale, enabling advanced automation, decision-making, and real-time AI experiences.
- Sovereign-ready scalability – Deploy high-performance AI in-country with full sovereign controls, supporting secure operations in regulated sectors such as healthcare, finance, and national security.
- Optimized for committed environments – Deliver fast, scalable AI in-country with sovereign controls for organizations operating under committed infrastructure agreements, ensuring predictable cost and performance.
- Cost-efficient agentic AI – Run agentic workloads at the lowest possible cost while maintaining in-country deployment and sovereign controls, making advanced AI accessible to cost-sensitive use cases.
Available now through Compass API, these models let organizations run and adapt AI locally or in the cloud, with full transparency, fine-tuning, and sovereign deployment options. Customers can align performance, cost, and compliance to their needs.
This release marks a pivotal move toward enterprise AI autonomy. With open-weight access, businesses can shape AI to their unique needs and unlock new possibilities for innovation at scale.
This announcement builds on G42’s recent milestones, including the unveiling of a 5GW US-UAE AI campus and the launch of the 1GW Stargate UAE facility as Phase 1 of the project, as well as a $1.5 billion investment from Microsoft in 2024, reinforcing the UAE’s role as a global AI hub.
For more information, visit https://aicloud.core42.ai/gpt-oss and https://aicloud.core42.ai
About Core42
Core42, a G42 company, empowers individuals, enterprises, and nations to unlock the full potential of AI through its comprehensive enablement capabilities. As a leading provider of sovereign cloud, AI infrastructure, and services, our mission is to accelerate the achievements of others and help them reach their most ambitious goals.
To learn more, please visit www.core42.ai and follow Core42 LinkedIn, Core42 Instagram, Core42 X
About G42
G42 is a global leader in creating visionary artificial intelligence capabilities for a better tomorrow. Born in Abu Dhabi and operating around the world, G42 champions AI as a powerful force for good. Its people are constantly reimagining what technology can do, applying advanced thinking and innovation to accelerate progress and tackle society’s most pressing problems.
G42 is joining forces with nations, corporations and individuals to create the infrastructure for tomorrow’s world. From molecular biology to space exploration and everything in between, G42 realizes exponential possibilities, today.
For further information visit www.g42.ai
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250813769317/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom